drugset / Trial / NCT03716024

Study the Efficacy and Safety of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)

NCT03716024

Phase 2 Completed 234 enrolled Paratek Pharmaceuticals Inc
RandomizedParallel-groupTriple-blindTreatment

Summary

A Phase II trial to demonstrate the safety and efficacy of PTK 0796 in the treatment of complicated skin and skin structure infections (cSSSI).

Timeline

Start
2007-07-18
Primary completion
2008-01-07
Completion
2008-01-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Linezolid Other / unclassified 600 mg Intravenous
Subject Omadacycline Small molecule 100 mg Intravenous